Articles On Nanollose (ASX:NC6)
Title | Source | Codes | Date |
---|---|---|---|
October Health Winners: Uscom, Respiri lead sluggish sector, but ‘time in the market, not timing, is key’
ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th... |
Stockhead | NC6 | 3 weeks ago |
Closing Bell: ASX dips as AGL stalls; Talga skyrockets after Sweden approves graphite mine
ASX slips amid earnings updates and company meetings AGL drops over 6pc after downgrade, while Origin Energy rises Talga surges after Sweden approves graphite mine The ASX slipped by 0.22% after being dragged by a flurry of company... |
Stockhead | NC6 | 3 weeks ago |
September
Health Winners: EZZ and Althea lead upbeat sector sparked by Fed rate cut
Healthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as Fed cuts rates How ASX biotechs performed in the month of September The S&P 500 Health Care Index, a key world benchmark for health... |
Stockhead | NC6 | 1 month ago |
Closing Bell: Investors rush to mining stocks after China news; while Star crashes 40pc to new low
ASX rises modestly with mining stocks leading gains Fortescue surges nearly 5pc as iron ore prices climb Star Entertainment plunges over 40pc after trading halt lifted The ASX rose modestly by 0.1% on Friday, buoyed by a surge in min... |
Stockhead | NC6 | 1 month ago |
Closing Bell: ASX lifts as RBA holds; Element 25 boosts its battery plans with big US grant
ASX down as RBA holds rates steady again Element 25 lands US$166m grant talks Supermarket stocks drop again amid discount claims backlash The ASX was down 0.3% at one point but rallied to a flattish close after the Reserve Bank kept in... |
Stockhead | NC6 | 2 months ago |
August Health Winners: LTR Pharma, Control Bionics lead sector at the ‘cusp of an extraordinary era’
ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment The ASX Healthcare Index (AS... |
Stockhead | NC6 | 2 months ago |
Closing Bell: ASX slides as Qantas’ profit takes big dip; MC Mining triples on Chinese coal deal
The ASX lagged on Thursday after Nvidia’s disappointing Q3 guidance Mineral Resources fell 8pc off a major profit drop Qantas saw a 28pc drop in profit but saw modest share price gains The ASX was sluggish on Thursday, down 0.33%, follo... |
Stockhead | NC6 | 2 months ago |
July Health Winners: Oncosil, Zelira lead as ASX biotechs power through another strong month
S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July The S&P/ASX 200 Health Care index [XHJ]... |
Stockhead | NC6 | 3 months ago |
Closing Bell: Australian stocks are higher, stronger, faster
ASX rises on Thursday Nine sectors end higher, led by property stocks Small caps led by BEZ The local benchmark index hit a record high this morning before trimming gains late. The S&P/ASX200 closed up Thursday, gaining 22.40 poi... |
Stockhead | NC6 | 3 months ago |
Check Up: Europe delivers blow to Alzheimer’s research; and recent ASX health stock winners
The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month In a major blow for... |
Stockhead | NC6 | 3 months ago |
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape
The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase... |
Stockhead | NC6 | 4 months ago |
Closing Bell: A very hot ASX banks on big banks after big central banks start cutting
Aussie shares rally Rate sensitive stocks gain, led by Tech FTL soars on Newfoundland deal Aussie shares climbed strongly on Thursday closing above 7,820 as major global central banks began to cut interest rates and in the US, the S&... |
Stockhead | NC6 | 5 months ago |
ASX Health Winners in May: LTR Pharma leads, and why hopes are high for biotech stocks this year
S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month The S&P/ASX 200 Health Care [XHJ] closed flattish for the month o... |
Stockhead | NC6 | 5 months ago |
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners
Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month The phrase ‘you are what you eat’ was coined almost a c... |
Stockhead | NC6 | 6 months ago |
Closing Bell: Webjet to split, BHP’s deadline dilemma, and Charger Metals up 70pc on lithium find
Tesltra slumps, iron ore miners gain BHP faces a deadline today to decide on its bid for Anglo America Webjet reveals plans to split its travel divisions, boosting its share price today The ASX 200 closed flattish on Wednesday, as big l... |
Stockhead | NC6 | 6 months ago |
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different
ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month The S&P/ASX 200 Health Care [XHJ] had a soft month in April... |
Stockhead | NC6 | 6 months ago |
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners
There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month Scientists have made a significant b... |
Stockhead | NC6 | 7 months ago |
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month
ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr... |
Stockhead | NC6 | 8 months ago |
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs
Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks There were a couple of big news from the world of biotec... |
Stockhead | NC6 | 8 months ago |
Closing Bell: Local markets ride commodities higher after a blow to US confidence on Friday
Local markets ride commodities lift to offset weak performance from Wall Street on Friday ASX 200 benchmark finished the day on +0.09pc, a lot higher than it really had any right to Resources led the way, overcoming a significant deadwei... |
Stockhead | NC6 | 9 months ago |
Closing Bell: Blood plasma giant CSL bleeds out in front of entire ASX on Monday
ASX200 dragged down by bad drugs The IT Sector is up 1.1pc, Healthcare is down about 3.2pc Small cap winners led by American Rare Earths and Appen The benchmark was shot through the heart by CSL this morning leaving everything else in... |
Stockhead | NC6 | 9 months ago |
Top 10 at 11: Boardroom battles and spinning drills are driving the market this morning
Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the trading day by... |
Stockhead | NC6 | 1 year ago |
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners
Xi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks China’s President Xi is expected... |
Stockhead | NC6 | 1 year ago |
Closing Bell: Friday takes a bite out of ASX, even as biotech and lithium small caps run amok
The ASX has ended the week lower, down 0.55pc on Friday Healthcare Sector remains defiant Small caps led by medtech names and Lake Johnston lithium hunters The fickle Aussie sharemarket has given back on Friday all that it has made thi... |
Stockhead | NC6 | 1 year ago |
Closing Bell: ASX in disgrace after crashing to 12-month low
Benchmark ASX index ends -0.6 lower Utilities only sector in the green Small caps led by LSA, AZS The ASX200 has closed 42 points (-0.61%) lower on Thursday. May as well get you a pic. I’ll point out the important bits… ASX200 ON THUR... |
Stockhead | NC6 | 1 year ago |
Closing Bell: ASX ends flat, but it’s not a good flat. More an Oxford Dictionary ‘to lack vigour; dull and lifeless’ flat
Benchmark ASX index closes short by -0.04% Materials sector tries but cannot offset everyone else Small caps led by HAL, DTC The ASX200 Index has closed slightly lower after jumping early (+0.3%) out the gates on Wednesday morning. The... |
Stockhead | NC6 | 1 year ago |
Closing Bell: ASX unconvincing ahead of big CPI read and maiden address by new RBA boss
Benchmark ASX index closes ahead +0.19% Materials lead ASX sectors on Tuesday Small caps led by ERW, NMR Local markets have struggled to hang onto early gains after a mixed run on Wall Street overnight. The benchmark ASX200 (XJO) index... |
Stockhead | NC6 | 1 year ago |
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff
News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks Goldman Sachs analysts said they will make no... |
Stockhead | NC6 | 1 year ago |
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it
L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks Be... |
Stockhead | NC6 | 1 year ago |
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?
The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks On... |
Stockhead | NC6 | 1 year ago |
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…
Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August August was all about earnings, and des... |
Stockhead | NC6 | 1 year ago |
Check Up: Australian biotech sector continues to be a magnet for US investors
Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the best and worst performing ASX biotechs over the past month The Australian biotech sector co... |
Stockhead | NC6 | 1 year ago |
Top 10 at 10-ish: Great White win for Andromeda, but things aren’t so great for EMS
Stockhead’s Top 10 at 11, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers... |
Stockhead | NC6 | 1 year ago |
Closing Bell: ASX rises despite tech meltdown; Domino’s fires everyone, stock jumps
ASX 200 benchmark climbs 0.5% Tech Sector plunges 5.5% while Consumer stocks and iron ore majors save day Small cap gains led by huge day at 4DS The Australian share market extracted some green from a dull Wednesday wicket after the Wa... |
Stockhead | NC6 | 1 year ago |
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go
Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month Steve Jobs used to say that the most... |
Stockhead | NC6 | 1 year ago |
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback
The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July The Covid-19 pandemic had produced windfalls for and attracted fa... |
Stockhead | NC6 | 1 year ago |
In Case You Missed It: Data centres, gold and cannabis take the lead
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | NC6 | 1 year ago |
CLOSING BELL: ASX rises 1.5pc today, with the Goldies out in front on 3.54pc
ASX snaps a 4-day run of bruising luck with a welcome 1.5% gain Techies did a lot of the heavy lifting, while the Goldies put on a +3.54% show The day’s clear winner was Mobilicom, up 150% at day’s end on juicy defence news Local market... |
Stockhead | NC6 | 1 year ago |
CLOSING BELL: ASX falters with no US market to copy today
S&P/ASX 200 closes in the red today: -0.35%, as US stock markets enjoy a July 4 chilli dog, or something Sectors-wise, Telcos are ringing in the gainz… annnd that’s about it. Okay, Utilities are going alright Standout stocks: Krakatoa... |
Stockhead | NC6 | 1 year ago |
In Case You Missed It: Lithium, nickel and a Peruvian divestment deal
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | NC6 | 1 year ago |
In Case You Missed It: Rare earths, lithium and a dash of nickel
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | NC6 | 1 year ago |
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines
Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month The world is anticipating a “game changer” as Brisba... |
Stockhead | NC6 | 1 year ago |
In Case You Missed It: Gold, rare earths and a digital healthcare deal
Stockhead’s In-Case-You-Missed-It highlights some strongest-performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | NC6 | 1 year ago |
In Case You Missed It: Lithium, iron ore, and iron ore switching to lithium
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | NC6 | 1 year ago |
Less swings, more roundabouts for these ASX companies driving the circular economy
Several ASX companies are driving Australia’s circular economy, prioritising resource conservation and sustainability Nanollose is working to produce tree-free cellulose, instead using an eco-friendly fermentation process to grow fibres... |
Stockhead | NC6 | 1 year ago |
In Case You Missed It: Nickel hits, Canadian lithium and some more nickel
Stockhead’s In-Case-You-Missed-It highlights some strongest-performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | NC6 | 1 year ago |
In Case You Missed It: Tech takeover takes the cake
Stockhead’s In-Case-You-Missed-It highlights some of the strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentag... |
Stockhead | NC6 | 1 year ago |
In Case You Missed It: Spectacular gold, an authentication deal and some lithium
Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today. It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms... |
Stockhead | NC6 | 1 year ago |
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends
Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week When we talk about dividend-paying hea... |
Stockhead | NC6 | 1 year ago |
ASX Biotech Winners in May: We’re finally seeing signs of life on the back of another clinical breakthrough
Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May There are clear signs the biotech sector is springing back to life after a disappointing 2... |
Stockhead | NC6 | 1 year ago |